1、In an unceasingly complex environment,how can MedTech adapt to thrive?Pulse of the MedTech Industry Report 2024ContentsTo our clients and friends3The year in review The MedTech landscape in 20244EY perspectiveTaking on the top-line challenge:Where can MedTech go to find growth?14Guest perspectiveBos

2、ton Scientifics growth playbook:M&A,R&D and global market execution18EY perspectiveMedTech manufacturers struggle for profitability as input costs rise21Guest perspectiveHow J&J MedTech balances organic growth with strategic acquisitions24EY perspective Turning MedTechs commercial challenges into tr

3、ue growth opportunities27EY perspective The rise of AI is shifting the MedTech landscape and where its going31Guest perspectiveThe role of AI in MedTechs future:a deep dive with AdvaMed35EY perspective Seizing the moment:MedTechs opportunity to enter consumer health39Databook42Financial performance4

4、3Financing46Merger and acquisition(M&A)52Data exhibit index54Acknowledgments5502Pulse of the MedTech Industry Report 2024Arda Ural,PhD EY Americas Life Sciences Sector Leader Ernst&Young LLPTo our clients and friendsJohn Babitt EY Americas MedTech Transactions Leader Ernst&Young LLPJim Welch EY Glob

5、al MedTech Leader Ernst&Young LLPThe 18th annual Pulse of the MedTech Industry Report finds the medical technology(MedTech)industry still progressing and growing but,increasingly,walking a narrow path between converging top-line and bottom-line pressures.MedTech recorded its sixth successive year of

6、 unbroken top-line growth and is now a US$587 billion industry.It continues to innovate,with 2023 showing a record number of FDA product authorizations,both pre-market approvals(PMAs)and 510(k)approvals,and the new products reaching the market include highly differentiated launches in areas such as